1. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva: World Health Organization; 2011.
2. Guidelines for treatment of drug-susceptible tuberculosis and patient care – 2017 update. Geneva: World Health Organization; 2017.
3. WHO consolidated guidelines on tuberculosis. Module 5: Co-morbidities, vulnerable populations and people-centred care. Management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022.
4. WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
5. WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022.
6. Guidance on ethics of tuberculosis prevention, care and control. Geneva: World Health Organization; 2010.
7. Ethics guidance for the implementation of the End TB strategy. Geneva: World Health Organization; 2017.
8. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345(8964):1545–8.
9. Kamolratanakul P, Sawert H, Lertmaharit S, Kasetjaroen Y, Akksilp S, Tulaporn C et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg. 1999;93(5):552–7.
10. MacIntyre CR, Goebel K, Brown GV, Skull S, Starr M, Fullinfaw RO. A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developedcountry setting. Int J Tuberc Lung Dis. 2003;7(9):848–54.
11. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre. Int J Tuberc Lung Dis. 1997;1(6):509–17.
12. Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet. 2001;357(9257):664–9.
13. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of selfsupervised and directly observed treatment of tuberculosis. Lancet. 1998;352(9137):1340–3.
14. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. Int J Tuberc Lung Dis. 2000;4(6):550–4.
15. Tandon M, Gupta M, Tandon S, Gupta KB. DOTS versus self administered therapy (SAT) for patients of pulmonary tuberculosis: a randomised trial at a tertiary care hospital. Indian J Med Sci. 2002;56(1):19–21.
16. Akkslip S, Rasmithat S, Maher D, Sawert H. Direct observation of tuberculosis treatment by supervised family members in Yasothorn Province, Thailand. Int J Tuberc Lung Dis. 1999;3(12):1061–5.
17. Balasubramanian VN, Oommen K, Samuel R. DOT or not? Direct observation of anti-tuberculosis treatment and patient outcomes, Kerala State, India. Int J Tuberc Lung Dis. 2000;4(5):409–13. 
18. Mathema B, Pande SB, Jochem K, Houston RA, Smith I, Bam DS et al. Tuberculosis treatment in nepal: a rapid assessment of government centers using different types of patient supervision. Int J Tuberc Lung Dis. 
19. Ormerod LP, Horsfield N, Green RM. Tuberculosis treatment outcome monitoring: Blackburn 1988–2000. Int J Tuberc Lung Dis. 2002;6(8):662–5.
20. Tsuchida K, Koyanagi H. Outcome of directly observed therapy for tuberculosis in Yokohama City, Japan. Int J Tuberc Lung Dis. 2003;7(8):730–4.
21. Nirupa C. Sudha G, Santha T, Ponnuraja C, Fathima R, Chandrasekharam V et al. Evaluation of directly observed treatment providers in the revised National Tuberculosis Control Programme. Indian J Tuberc. 2005;52:73–7.
22. Daniel OJ. Pre- and post-directly observed treatment era in the management of TB: a teachiing hospital experience. Trop Doct. 2006;36(3):163–5.
23. Okanurak K, Kitayaporn D, Wanarangsikul W, Koompong C. Effectiveness of DOT for tuberculosis treatment outcomes: a prospective cohort study in Bangkok, Thailand. Int J Tuberc Lung Dis. 2007;11(7):762–8.
24. Abassi A, Mansourian AR. Efficacy of DOTS strategy in treatment of respiratory tuberculosis in Gorgan, Islamic Republic of Iran. East Mediterr Health J. 2007;13(3):664–9.
25. Siemion-Szcześniak I, Kuś J. [Treatment outcomes in culture-positive pulmonary tuberculosis]. Pneumonol Alergol Pol. 2009;77(1):11–22.
26. Caylà JA, Rodrigo T, Ruiz-Manzano J, Caminero JA, Vidal R, García JM et al. Tuberculosis treatment adherence and fatality in Spain. Respir Res. 2009;10:121.
27. Zvavamwe Z, Ehlers VJ. Experiences of a community-based tuberculosis treatment programme in Namibia: a comparative cohort study. Int J Nurs Stud. 2009;46(3):302–9.
28. Xu W, Lu W, Zhou Y, Zhu L, Shen H, Wang J. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res. 2009;9:169.
29. Abuaku B, Tan H, Li X, Chen M, Huang X. Treatment default and death among tuberculosis patients in Hunan, China. Scand J Infect Dis. 2010;42(4):281–7.
30. Ershova JV, Podewils LJ, Bronner LE, Stockwell HG, Dlamini SS, Mametja LD. Evaluation of adherence to national treatment guidelines among tuberculosis patients in three provinces of South Africa. S Afr Med J. 2014;104(5):362–8.
31. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330(17):1179–84.
32. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest. 2001;120(5):1514–9.
33. Ollé-Goig JE, Alvarez J. Treatment of tuberculosis in a rural area of Haiti: directly observed and non-observed regimens. The experience of Hôpital Albert Schweitzer. Int J Tuberc Lung Dis. 2001;5(2):137–41.
34. Pungrassami P, Johnsen SP, Chongsuvivatwong V, Olsen J. Has directly observed treatment improved outcomes for patients with tuberculosis in southern Thailand? Trop Med Int Health. 2002;7(3):271–9.
35. Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med. 2004;170(5):561–6.
36. Cavalcante SC, Soares EC, Pacheco AG, Chaisson RE, Durovni B, Team DE. Community DOT for tuberculosis in a Brazilian favela: comparison with a clinic model. Int J Tuberc Lung Dis. 2007;11(5):544–9.
37. Radilla-Chávez P, Laniado-Laborín R. Results of directly observed treatment for tuberculosis in Ensenada, Mexico: not all DOTS programs are created equally. Int J Tuberc Lung Dis. 2007;11(3):289–92.
38. Anuwatnonthakate A, Limsomboon P, Nateniyom S, Wattanaamornkiat W, Komsakorn S, Moolphate S et al. Directly observed therapy and improved tuberculosis treatment outcomes in Thailand. PLoS One. 2008;3(8):e3089.
39. Kapella BK, Anuwatnonthakate A, Komsakorn S, Moolphate S, Charusuntonsri P, Limsomboon P et al. Directly observed treatment is associated with reduced default among foreign tuberculosis patients in Thailand. Int J Tuberc Lung Dis. 2009;13(2):232–7.
40. Vieira AA, Ribeiro SA. Compliance with tuberculosis treatment after the implementation of the directly observed treatment, short-course strategy in the city of Carapicuíba, Brazil. J Bras Pneumol. 2011;37(2):223–31.
41. Ong’ang’o JR, Mwachari C, Kipruto H, Karanja S. The effects on tuberculosis treatment adherence from utilising community health workers: a comparison of selected rural and urban settings in Kenya. PLoS One. 2014;9(2):e88937.
42. Das M, Isaakidis P, Armstrong E, Gundipudi NR, Babu RB, Qureshi IA et al. Directly-observed and selfadministered tuberculosis treatment in a chronic, low-intensity conflict setting in India. PLoS One. 2014;9(3):e92131.
43. Alwood K, Keruly J, Moore-Rice K, Stanton DL, Chaulk CP, Chaisson RE. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS. 1994;8(8):1103–8.
44. Alvarez-Uria G, Midde M, Pakam R, Naik PK. Directly-observed intermittent therapy versus unsupervised daily regimen during the intensive phase of antituberculosis therapy in HIV infected patients. Biomed Res Int. 2014;2014:937817.
45. Juan G, Lloret T, Perez C, Lopez P, Navarro R, Ramón M et al. Directly observed treatment for tuberculosis in pharmacies compared with self-administered therapy in Spain. Int J Tuberc Lung Dis. 2006;10(2):215–21.
46. Caylà JA, Caminero JA, Rey R, Lara N, Vallés X, Galdós-Tangüis H et al. Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis. 2004;8(4):458–64.
47. Colvin M, Gumede L, Grimwade K, Maher D, Wilkinson D. Contribution of traditional healers to a rural tuberculosis control programme in Hlabisa, South Africa. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S86–91.
48. Singh AA, Parasher D, Shekhavat GS, Sahu S, Wares DF, Granich R. Effectiveness of urban community volunteers in directly observed treatment of tuberculosis patients: a field report from Haryana, North India. Int J Tuberc Lung Dis. 2004;8(6):800–2.
49. Kingkaew N, Sangtong B, Amnuaiphon W, Jongpaibulpatana J, Anuwatnonthakate A. Effectiveness of and results from directly observed treatment of tuberculosis patients by health-care workers vs. family members, Vachira Phuket Hospital, 2005–2006. J Health Syst Res. 2008;2(2):1127–34.
50. Tripathy SK, Kumar P, Sagili KD, Enarson DA. Effectiveness of a community-based observation of antituberculosis treatment in Bangalore City, India, 2010–2011. Public Health Action. 2013;3(3):230–4.
51. Wilkinson D, Davies GR. Coping with Africa’s increasing tuberculosis burden: are community supervisors an essential component of the DOT strategy? Directly observed therapy. Trop Med Int Health. 1997;2(7):700–4.
52. Lwilla F, Schellenberg D, Masanja H, Acosta C, Galindo C, Aponte J et al. Evaluation of efficacy of community based vs. institutional-based direct observed short-course treatment for the control of tuberculosis in Kilombero district, Tanzania. Trop Med Int Health. 2003;8(3):204–10.
53. Wandwalo E, Kapalata N, Egwaga S, Morkve O. Effectiveness of community-based directly observed treatment for tuberculosis in an urban setting in Tanzania: a randomised controlled trial. Int J Tuberc Lung Dis. 2004;8(10):1248–54.
54. Wright J, Walley J, Philip A, Pushpananthan S, Dlamini E, Newell J et al. Direct observation of treatment for tuberculosis: a randomized controlled trial of community health workers versus family members. Trop Med Int Health. 2004;9(5):559–65.
55. Newell JN, Baral SC, Pande SB, Bam DS, Malla P. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet. 2006;367(9514):903–9.
56. Farmer P, Robin S, Ramilus SL, Kim JY. Tuberculosis, poverty, and “compliance”: lessons from rural Haiti. Semin Respir Infect. 1991;6(4):254–60.
57. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004;170(12):1360–6.
58. Soares EC, Vollmer WM, Cavalcante SC, Pacheco AG, Saraceni V, Silva JS et al. Tuberculosis control in a socially vulnerable area: a community intervention beyond DOT in a Brazilian favela. Int J Tuberc Lung Dis. 2013;17(12):1581–6.
59. Yassin MA, Datiko DG, Tulloch O, Markos P, Aschalew M, Shargie EB et al. Innovative community-based approaches doubled tuberculosis case notification and improve treatment outcome in southern Ethiopia. PLoS One. 2013;8(5):e63174.
60. Chan PC, Huang SH, Yu MC, Lee SW, Huang YW, Chien ST et al. Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients – a retrospective cohort study. PLoS One. 2013;8(2):e57719.
61. Gärden B, Samarina A, Stavchanskaya I, Alsterlund R, Övregaard A, Taganova O et al. Food incentives improve adherence to tuberculosis drug treatment among homeless patients in Russia. Scand J Caring Sci. 2013;27(1):117–22.
62. Davidson BL. A controlled comparison of directly observed therapy vs self-administered therapy for active tuberculosis in the urban United States. Chest. 1998;114(5):1239–43.
63. Puchalski Ritchie LM, Schull MJ, Martiniuk AL, Barnsley J, Arenovich T, van Lettow M et al. A knowledge translation intervention to improve tuberculosis care and outcomes in Malawi: a pragmatic cluster randomized controlled trial. Implement Sci. 2015;10:38.
64. Datiko DG, Lindtjørn B. Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial. PLoS One. 2009;4(5):e5443.
65. Clark PM, Karagoz T, Apikoglu-Rabus S, Izzettin FV. Effect of pharmacist-led patient education on adherence to tuberculosis treatment. Am J Health Syst Pharm. 2007;64(5):497–505.
66. Janmeja AK, Das SK, Bhargava R, Chavan BS. Psychotherapy improves compliance with tuberculosis treatment. Respiration. 2005;72(4):375–80.
67. Liefooghe R, Suetens C, Meulemans H, Moran MB, De Muynck A. A randomised trial of the impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan. Int J Tuberc Lung Dis. 1999;3(12):1073–80.
68. Baral SC, Aryal Y, Bhattrai R, King R, Newell JN. The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot intervention studies. BMC Public Health. 2014;14:46.
69. Martins N, Morris P, Kelly PM. Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste. BMJ. 2009;339:b4248.
70. Lutge E, Lewin S, Volmink J, Friedman I, Lombard C. Economic support to improve tuberculosis treatment outcomes in South Africa: a pragmatic cluster-randomized controlled trial. Trials. 2013;14:154.
71. Jahnavi G, Sudha CH. Randomised controlled trial of food supplements in patients with newly diagnosed tuberculosis and wasting. Singapore Med J. 2010;51(12):957–62.
72. Sinclair D, Abba K, Grobler L, Sudarsanam TD. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev. 2011(11):CD006086.
73. Álvarez Gordillo G.C. AGJ, Dorantes Jimenez J., . Estrategia educativa para incrementar el cumplimiento del régimen antituberculoso en Chiapas. Pan Am J Public Heal. 2003;14(6):402–8.
74. Demissie M, Getahun H, Lindtjørn B. Community tuberculosis care through “TB clubs” in rural North Ethiopia. Soc Sci Med. 2003;56(10):2009–18.
75. Dick J, Lombard C. Shared vision – a health education project designed to enhance adherence to antituberculosis treatment. Int J Tuberc Lung Dis. 1997;1(2):181–6.
76. Banerjee A, Harries AD, Mphasa N, Nyirenda TE, Veen J, Ringdal T et al. Evaluation of a unified treatment regimen for all new cases of tuberculosis using guardian-based supervision. Int J Tuberc Lung Dis. 2000;4(4):333–9.
77. Becx-Bleumink M, Wibowo H, Apriani W, Vrakking H. High tuberculosis notification and treatment success rates through community participation in central Sulawesi, Republic of Indonesia. Int J Tuberc Lung Dis. 2001;5(10):920–5.
78. Dobler CC, Korver S, Batbayar O, Oyuntsetseg S, Tsolmon B, Wright C et al. Success of community-based directly observed anti-tuberculosis treatment in Mongolia. Int J Tuberc Lung Dis. 2015;19(6):657–62.
79. Dudley L, Azevedo V, Grant R, Schoeman JH, Dikweni L, Maher D. Evaluation of community contribution to tuberculosis control in Cape Town, South Africa. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S48–55.
80. Maciel EL, Guidoni LM, Brioshi AP, do Prado TN, Fregona G, Hadad DJ et al. Household members and health care workers as supervisors of tuberculosis treatment. Rev Saude Publica. 2010;44(2):339–43.
81. Miti S, Mfungwe V, Reijer P, Maher D. Integration of tuberculosis treatment in a community-based home care programme for persons living with HIV/AIDS in Ndola, Zambia. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S92–8.
82. Moalosi G, Floyd K, Phatshwane J, Moeti T, Binkin N, Kenyon T. Cost-effectiveness of home-based care versus hospital care for chronically ill tuberculosis patients, Francistown, Botswana. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S80–5.
83. Niazi AD, Al-Delaimi AM. Impact of community participation on treatment outcomes and compliance of DOTS patients in Iraq. East Mediterr Health J. 2003;9(4):709–17.
84. Wares DF, Akhtar M, Singh S. DOT for patients with limited access to health care facilities in a hill district of eastern Nepal. Int J Tuberc Lung Dis. 2001;5(8):732–40.
85. Arora V. K. NSN, Gupta R.. Community mediated domiciliary DOTS execution – a study from New Delhi. Ind J Tub. 2003;50:143.
86. Kironde S, Meintjies M. Tuberculosis treatment delivery in high burden settings: does patient choice of supervision matter? Int J Tuberc Lung Dis. 2002;6(7):599–608.
87. van den Boogaard J, Lyimo R, Irongo CF, Boeree MJ, Schaalma H, Aarnoutse RE et al. Community vs. facilitybased directly observed treatment for tuberculosis in Tanzania’s Kilimanjaro Region. Int J Tuberc Lung Dis. 2009;13(12):1524–9.
88. Manders AJ, Banerjee A, van den Borne HW, Harries AD, Kok GJ, Salaniponi FM. Can guardians supervise TB treatment as well as health workers? A study on adherence during the intensive phase. Int J Tuberc Lung Dis. 2001;5(9):838–42.
89. Akhtar S, Rozi S, White F, Hasan R. Cohort analysis of directly observed treatment outcomes for tuberculosis patients in urban Pakistan. Int J Tuberc Lung Dis. 2011;15(1):90–6.
90. Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc Lung Dis. 2016;20(5):588–93.
91. Wade VA, Karnon J, Eliott JA, Hiller JE. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLoS One. 2012;7(11):e50155.
92. Khortwong P, Kaewkungwal J. Thai health education program for improving TB migrant’s compliance. J Med Assoc Thai. 2013;96(3):365–73.
93. Morisky DE, Malotte CK, Choi P, Davidson P, Rigler S, Sugland B et al. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q. 1990;17(3):253–67.
94. Drabo M, Zerbo R, Berthe A, Ouedrago L, Konfe S, Mugishe E et al. [Community involvement in tuberculosis care in three rural health districts of Burkina Faso]. Santé Publique. 2009;21(5):485–97.
95. Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, Fielding KL et al. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. Jama. 2007;297(4):380–6.
96. Hsieh CJ, Lin LC, Kuo BI, Chiang CH, Su WJ, Shih JF. Exploring the efficacy of a case management model using DOTS in the adherence of patients with pulmonary tuberculosis. J Clin Nurs. 2008;17(7):869–75.
97. Atkins S, Lewin S, Jordaan E, Thorson A. Lay health worker-supported tuberculosis treatment adherence in South Africa: an interrupted time-series study. Int J Tuberc Lung Dis. 2011;15(1):84–9.
98. Iribarren S, Chirico C, Echevarria M, Cardinali D. TextTB: A parallel design randomized control pilot study to evaluate acceptance and feasibility of a patient-driven mobile phone based intervention to support adherence to TB treatment. J Mob Technol Med. 2012;1(4S):23–4.
99. Krishnaswami KV, Somasundaram PR, Tripathy SP, Vaidyanathan B, Radhakrishna S, Fox W. A randomised study of two policies for managing default in out-patients collecting supplies of drugs for pulmonary tuberculosis in a large city in South India. Tubercle. 1981;62(2):103–12.
100. Kunawararak P, Pongpanich S, Chantawong S, Pokaew P, Traisathit P, Srithanaviboonchai K et al. Tuberculosis treatment with mobile-phone medication reminders in northern Thailand. Southeast Asian J Trop Med Public Health. 2011;42(6):1444–51.
101. Mohan A, Nassir H, Niazi A. Does routine home visiting improve the return rate and outcome of DOTS patients who delay treatment? East Mediterr Health J. 2003;9(4):702–8.
102. Paramasivan R, Parthasarathy RT, Rajasekaran S. Short course chemotherapy: a controlled study of indirect defaulter retrieval method. Indian J Tuberc. 1993;40:185–90.
103. Tanke ED, Leirer VO. Automated telephone reminders in tuberculosis care. Med Care. 1994;32(4):380–9.
104. Moulding TS, Caymittes M. Managing medication compliance of tuberculosis patients in Haiti with medication monitors. Int J Tuberc Lung Dis. 2002;6(4):313–9.
105. Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med. 2015;12(9):e1001876.
106. Bronner LE, Podewils LJ, Peters A, Somnath P, Nshuti L, van der Walt M et al. Impact of community tracer teams on treatment outcomes among tuberculosis patients in South Africa. BMC Public Health. 2012;7(12):621.
107. Snidal SJ, Barnard G, Atuhairwe E, Amor YB. Use of eCompliance, an innovative biometric system for monitoring of tuberculosis treatment in rural Uganda. Am J Trop Med Hyg. 2015;92(6):1271–9.
108. Thomson KA, Cheti EO, Reid T. Implementation and outcomes of an active defaulter tracing system for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB patients in Kibera, Nairobi, Kenya. Trans R Soc Trop Med Hyg. 2011;105(6):320–6.
109. Al-Hajjaj MS, Al-Khatim IM. High rate of non-compliance with anti-tuberculosis treatment despite a retrieval system: a call for implementation of directly observed therapy in Saudi Arabia. Int J Tuberc Lung Dis. 2000;4(4):345–9.
110. Broomhead S, Mars M. Retrospective return on investment analysis of an electronic treatment adherence device piloted in the Northern Cape Province. Telemed e-Health. 2012;18(1):24–31.
111. Ngamvithayapong-Yanai J, Luangjina S, Nedsuwan S, Kantipong P, Wongyai J, Ishikawa N. Engaging women volunteers of high socioeconomic status in supporting socioeconomically disadvantaged tuberculosis patients in Chiang Rai, Thailand. WPSAR. 2013;4(1):34–8.
112. Zou G, Wei X, Witter S, Yin J, Walley J, Liu S et al. Incremental cost-effectiveness of improving treatment results among migrant tuberculosis patients in Shanghai. Int J Tuberc Lung Dis. 2013;17(8):1056–64.
113. Lu H, Yan F, Wang W, Wu L, Ma W, Chen J et al. Do transportation subsidies and living allowances improve tuberculosis control outcomes among internal migrants in urban Shanghai, China? WPSAR. 2013;4(1):19–24.
114. Wei X, Zou G, Yin J, Walley J, Yang H, Kliner M et al. Providing financial incentives to rural-to-urban tuberculosis migrants in Shanghai: an intervention study. Infect Dis Poverty. 2012;1(1):9.
115. Cantalice Filho JP. Food baskets given to tuberculosis patients at a primary health care clinic in the city of Duque de Caxias, Brazil: effect on treatment outcomes. J Bras Pneumol. 2009;35(10):992–7.
116. Sripad A, Castedo J, Danford N, Zaha R, Freile C. Effects of Ecuador’s national monetary incentive program on adherence to treatment for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2014;18(1):44–8.
117. Tsai W-C, Kung P-T, Khan M, Campbell C, Yang W-T, Lee T-F et al. Effects of pay-for-performance system on tuberculosis default cases control and treatment in Taiwan. J Infect. 2010;61(3):235–43.
118. Bock NN, Sales RM, Rogers T, DeVoe B. A spoonful of sugar...: improving adherence to tuberculosis treatment using financial incentives. Int J Tuberc Lung Dis. 2001;5(1):96–8.
119. Safdar N, Hinderaker SG, Baloch NA, Enarson DA, Khan MA, Morkve O. Childhood tuberculosis deskguide and monitoring: An intervention to improve case management in Pakistan. BMC Health Serv Res. 
120. Shin S, Livchits V, Connery HS, Shields A, Yanov S, Yanova G et al. Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia. Addiction. 2013;108(8):1387–96.
121. End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. eneva: World Health Organization; 2014.
122. Floyd K, Hutubessy R, Kliiman K, Centis R, Khurieva N, Jakobowiak W et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J. 2012;40(1):133–42.
123. Suárez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, Ramos G et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002;359(9322):1980–9.
124. Tupasi TE, Gupta R, Quelapio MID, Orillaza RB, Mira NR, Mangubat NV et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006;3(9):e352.
125. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrugresistant tuberculosis. PharmacoEconomics. 2012;30(1):63–80.
126. Chan P-C, Huang S-H, Yu M-C, Lee S-W, Huang Y-W, Chien S-T et al. Effectiveness of a governmentorganized and hospital-initiated treatment for multidrug-resistant tuberculosis patients – a retrospective cohort study. PLoS One. 2013;8(2):e57719.
127. Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, Poolman M et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014;18(4):441–8.
128. Gler MT, Podewils LJ, Munez N, Galipot M, Quelapio MID, Tupasi TE. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(7):955–60.
129. Loveday M, Wallengren K, Brust J, Roberts J, Voce A, Margot B et al. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2015;19(2):163–71.
130. Musa BM, John D, Habib AG, Kuznik A. Cost-optimization in the treatment of multidrug resistant tuberculosis n Nigeria. Trop Med Int Health. 2016;21(2):176–82.
131. Sinanovic E, Ramma L, Vassall A, Azevedo V, Wilkinson L, Ndjeka N et al. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis. 2015;19(2):172–8.
132. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment experience of multidrugresistant tuberculosis in Florida, 1994–1997. Chest. 2001;120(2):343–8.
133. Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bull World Health Organ. 2017;95(8):584–93.
134. WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva: World Health Organization; 2009.
135. Roadmap for childhood tuberculosis: towards zero deaths. Geneva: World Health Organization; 2013.
136. Roadmap towards ending TB in children and adolescents. Geneva: World Health Organization; 2018.
137. Public–private mix for TB prevention and care: a roadmap. Geneva: World Health Organization; 2018.
138. WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Care and support during tuberculosis treatment Geneva: World Health Organization; 2022.
139. Talukder K, Salim MA, Jerin I, Sharmin F, Talukder MQ, Marais BJ et al. Intervention to increase detection of childhood tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2012;16(1):70–5.
140. Khan AJ, Khowaja S, Khan FS, Qazi F, Lotia I, Habib A et al. Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. The Lancet Infectious diseases. 2012;12(8):608–16.
141. Malik AA, Amanullah F, Codlin AJ, Siddiqui S, Jaswal M, Ahmed JF et al. Improving childhood tuberculosis detection and treatment through facility-based screening in rural Pakistan. Int J Tuberc Lung Dis. 2018;22(8):851–7.
142. Zawedde-Muyanja S, Nakanwagi A, Dongo JP, Sekadde MP, Nyinoburyo R, Ssentongo G et al. Decentralisation of child tuberculosis services increases case finding and uptake of preventive therapy in Uganda. Int J Tuberc Lung Dis. 2018;22(11):1314–21.
143. Maha A, Majumdar SS, Main S, Phillip W, Witari K, Schulz J et al. The effects of decentralisation of tuberculosis services in the East New Britain Province, Papua New Guinea. Public Health Action. 2019;9(Suppl 1):S43–s9.
144. Islam Z, Sanin KI, Ahmed T. Improving case detection of tuberculosis among children in Bangladesh: lessons learned through an implementation research. BMC Public Health. 2017;17(1):131.
145. Catalyzing Pediatric TB Innovation (CaP-TB) project. [Unpublished data]. In press 2021.
146. Oshi DC, Chukwu JN, Nwafor CC, Meka AO, Madichie NO, Ogbudebe CL et al. Does intensified case finding increase tuberculosis case notification among children in resource-poor settings? A report from Nigeria. International journal of mycobacteriology. 2016;5(1):44–50.
147. Joshi B, Chinnakali P, Shrestha A, Das M, Kumar AM, Pant R et al. Impact of intensified case-finding strategies on childhood TB case registration in Nepal. Public Health Action. 2015;5(2):93–8.
148. Hanrahan CF, Nonyane BAS, Mmolawa L, West NS, Siwelana T, Lebina L et al. Contact tracing versus facility-based screening for active TB case finding in rural South Africa: a pragmatic cluster-randomized trial (Kharitode TB). PLoS Med. 2019;16(4):e1002796.
149. Moyo S, Verver S, Hawkridge A, Geiter L, Hatherill M, Workman L et al. Tuberculosis case finding for vaccine trials in young children in high-incidence settings: a randomised trial. Int J Tuberc Lung Dis. 2012;16(2):185–91.
150. Davis JL, Turimumahoro P, Meyer AJ, Ayakaka I, Ochom E, Ggita J et al. Home-based tuberculosis contact investigation in Uganda: a household randomised trial. ERJ Open Res. 2019;5(3).
151. Fatima R, Qadeer E, Yaqoob A, Haq Mu, Majumdar SS, Shewade HD et al. Extending ‘contact tracing’ into the community within a 50-metre radius of an index tuberculosis patient using Xpert MTB/RIF in urban Pakistan. Did it increase case detection? PLoS One. 2016;11(11):e0165813.
152. Reddy KK, Ananthakrishnan R, Jacob AG, Das M, Isaakidis P, Kumar AMV. Intensified tuberculosis case finding amongst vulnerable communities in southern India. Public health action. 2015;5(4):246–8.
153. Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2003;7(12 Suppl 3):S501–9.
154. Sachdeva KS, Raizada N, Sreenivas A, van’t Hoog AH, van den Hof S, Dewan PK et al. Use of Xpert MTB/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. PLoS One. 2015;10(5):e0126065.
155. Zachariah R, Spielmann MP, Harries AD, Gomani P, Graham SM, Bakali E et al. Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi. Int J Tuberc Lung Dis. 2003;7(11):1033–9.
156. Ketema L, Dememew ZG, Assefa D, Gudina T, Kassa A, Letta T et al. Evaluating the integration of tuberculosis screening and contact investigation in tuberculosis clinics in Ethiopia: a mixed method study. PLoS One. 2020;15(11):e0241977.
157. Miyano S, Dube C, Kayama N, Ishikawa N, Nozaki I, Syakantu G. Association between tuberculosis treatment outcomes and the mobile antiretroviral therapy programme in Zambia. Int J Tuberc Lung Dis. 2013;17(4):540–5.
158. Wingfield T, Tovar MA, Huff D, Boccia D, Montoya R, Ramos E et al. A randomized controlled study of socioeconomic support to enhance tuberculosis prevention and treatment, Peru. Bull World Health Organ. 2017;95(4):270–80.
159. Rocha C, Montoya R, Zevallos K, Curatola A, Ynga W, Franco J et al. The Innovative Socio-economic Interventions Against Tuberculosis (ISIAT) project: an operational assessment. Int J Tuberc Lung Dis. 2011;15(Suppl 2):50–7.
160. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
161. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
162. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization 2014.
163. Updated recommendations on service delivery for the treatment and care of people living with HIV. Geneva: World Health Organization; 2021.

Book navigation